Pharsight

Azurity patents expiration

1. Bidil patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6784177 AZURITY Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
Sep, 2020

(3 years ago)

US6465463 AZURITY Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
Sep, 2020

(3 years ago)

Drugs and Companies using HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE ingredient

Market Authorisation Date: 23 June, 2005

Treatment: Method of treatment of heart failure

Dosage: TABLET;ORAL

More Information on Dosage

BIDIL family patents

Family Patents

2. Edarbi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5583141 AZURITY Heterocyclic compounds and their use as angiotensin antagonists
Dec, 2013

(10 years ago)

US5958961 AZURITY Pharmaceutical composition for angiotensin II-mediated diseases
Jun, 2014

(9 years ago)

US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(7 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage

EDARBI family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Edarbyclor patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5583141 AZURITY Heterocyclic compounds and their use as angiotensin antagonists
Dec, 2013

(10 years ago)

US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(7 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(3 years from now)

US9169238 AZURITY Solid pharmaceutical composition
Feb, 2030

(5 years from now)

US9387249 AZURITY Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Dec 20, 2014
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 20 December, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's drug patent expiration?
More Information on Dosage

EDARBYCLOR family patents

Family Patents

4. Epaned patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10154987 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10772868 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US9808442 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11141405 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10039745 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11040023 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US11173141 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US10786482 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

US9669008 AZURITY Enalapril formulations
Mar, 2036

(11 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 20 September, 2016

Treatment: Treatment of heart failure; Treatment of hypertension

Dosage: SOLUTION;ORAL

How can I launch a generic of EPANED before it's drug patent expiration?
More Information on Dosage

EPANED family patents

Family Patents

5. Epaned Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9968553 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

US8568747 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

US8778366 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

US9855214 AZURITY Enalapril compositions
Nov, 2032

(8 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 13 August, 2013

Treatment: Treatment of heart failure; Method of treating left ventricular dysfunction

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of EPANED KIT before it's drug patent expiration?
More Information on Dosage

EPANED KIT family patents

Family Patents

6. Eprontia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826343 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11633374 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11911362 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

US11433046 AZURITY Compositions and methods for treating epilepsy, seizures and other conditions
Aug, 2040

(16 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 05 November, 2021

Treatment: Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage: SOLUTION;ORAL

How can I launch a generic of EPRONTIA before it's drug patent expiration?
More Information on Dosage

EPRONTIA family patents

Family Patents

7. Evekeo Odt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580 AZURITY Taste-masked pharmaceutical compositions
Apr, 2024

(a month ago)

US11160772 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)

US11896562 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)

US10441554 AZURITY Oral amphetamine composition
Mar, 2037

(12 years from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Market Authorisation Date: 16 April, 2021

Treatment: Treatment of attention deficit hyperactivity disorder (adhd) in pediatric patients

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

EVEKEO ODT family patents

Family Patents

8. Firvanq Kit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11638692 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10959949 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10688046 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10959948 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10959946 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10959947 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

US10493028 AZURITY Composition and method for vancomycin oral liquid
Mar, 2035

(10 years from now)

Drugs and Companies using VANCOMYCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of staphylococcal enterocolitis; Treatment of c. difficile-associated diarrhea

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of FIRVANQ KIT before it's drug patent expiration?
More Information on Dosage

FIRVANQ KIT family patents

Family Patents

9. Fleqsuvy patents expiration

Can you believe FLEQSUVY received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11446246 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(13 years from now)

US11324696 AZURITY Suspensions and diluents for metronidazole and baclofen
Sep, 2037

(13 years from now)

Drugs and Companies using BACLOFEN ingredient

Market Authorisation Date: 04 February, 2022

Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis

Dosage: SUSPENSION;ORAL

How can I launch a generic of FLEQSUVY before it's drug patent expiration?
More Information on Dosage

FLEQSUVY family patents

Family Patents

10. Horizant patents expiration

HORIZANT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6818787 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(10 months from now)

US8026279 AZURITY Crystalline form of γ-aminobutyric acid analog
Nov, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8048917 AZURITY Prodrugs of GABA analogs, compositions and uses thereof
Nov, 2022

(1 year, 6 months ago)

US8686034 AZURITY Crystalline form of γ-aminobutyric acid analog
Jan, 2025

(8 months from now)

US8114909 AZURITY Treating or preventing restless legs syndrome using prodrugs of GABA analogs
Apr, 2026

(1 year, 10 months from now)

US8795725 AZURITY GABA analog prodrug sustained release oral dosage forms
Jun, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Jun 06, 2019
Orphan Drug Exclusivity(ODE-25) Jun 06, 2019
New Chemical Entity Exclusivity(NCE) Apr 06, 2016
New Indication(I-652) Jun 06, 2015

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

NCE-1 date: 07 April, 2015

Market Authorisation Date: 13 December, 2011

Treatment: Management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of HORIZANT before it's drug patent expiration?
More Information on Dosage

HORIZANT family patents

Family Patents

11. Katerzia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10952998 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11484498 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11701326 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US10959991 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11471409 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11918685 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US11364230 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US10894039 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US10695329 AZURITY Amlodipine formulations
Oct, 2037

(13 years from now)

US10799453 AZURITY Amlodipine formulations
Apr, 2039

(14 years from now)

Drugs and Companies using AMLODIPINE BENZOATE ingredient

Market Authorisation Date: 08 July, 2019

Treatment: Angina; A method of treating hypertension; Method of treating hypertension

Dosage: SUSPENSION;ORAL

How can I launch a generic of KATERZIA before it's drug patent expiration?
More Information on Dosage

KATERZIA family patents

Family Patents

12. Konvomep patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11633478 AZURITY Compositions and kits for Omeprazole suspension
Jul, 2039

(15 years from now)

US11103492 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(15 years from now)

US11911473 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(15 years from now)

US10751333 AZURITY Compositions and kits for omeprazole suspension
Jul, 2039

(15 years from now)

US11771686 AZURITY Compositions and kits for omeprazole suspension
Mar, 2040

(15 years from now)

Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient

Market Authorisation Date: 30 August, 2022

Treatment: Reduction of risk of upper gastrointestinal bleeding in critically ill patients; Short term treatment of active benign gastric ulcer

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage

KONVOMEP family patents

Family Patents

13. Nymalize patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070581 AZURITY Dispenser for medicaments and method and apparatus for making same
Jun, 2023

(11 months ago)

US8517997 AZURITY Dispenser for medicaments and method and apparatus for making same
May, 2024

(10 days ago)

US11517563 AZURITY Liquid nimodipine compositions
Apr, 2038

(13 years from now)

US11806338 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(13 years from now)

US10576070 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(13 years from now)

US11759457 AZURITY Liquid nimodipine compositions
Apr, 2038

(13 years from now)

US10342787 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(13 years from now)

US11413277 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(13 years from now)

US11207306 AZURITY Non-aqueous liquid nimodipine compositions
Apr, 2038

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-46) May 10, 2020
Orphan Drug Exclusivity(ODE) May 10, 2020

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...

Dosage: SOLUTION;ORAL

How can I launch a generic of NYMALIZE before it's drug patent expiration?
More Information on Dosage

NYMALIZE family patents

Family Patents

14. Prevduo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11938217 AZURITY Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

US10456354 AZURITY Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

US11110054 AZURITY Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
Oct, 2038

(14 years from now)

Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient

Market Authorisation Date: 23 February, 2023

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PREVDUO family patents

Family Patents

15. Qbrelis patents expiration

QBRELIS IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463183 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9616096 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10039800 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10265370 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10940177 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US9814751 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11179434 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US10406199 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

US11771733 AZURITY Lisinopril formulations
Nov, 2035

(11 years from now)

Drugs and Companies using LISINOPRIL ingredient

Market Authorisation Date: 29 July, 2016

Treatment: Method of treatment of heart failure; Method of treating hypertension; Acute myocardial infarction

Dosage: SOLUTION;ORAL

How can I launch a generic of QBRELIS before it's drug patent expiration?
More Information on Dosage

QBRELIS family patents

Family Patents

16. Sotylize patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11013703 AZURITY Sotalol compositions and uses of the same
Apr, 2034

(9 years from now)

US10206895 AZURITY Sotalol compositions and uses of the same
Apr, 2034

(9 years from now)

US11850222 AZURITY Sotalol compositions and uses of the same
Nov, 2034

(10 years from now)

US9724297 AZURITY Sotalol compositions and uses of the same
Aug, 2035

(11 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2014

Treatment: Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening; Sotylize is indicated for the maintenanc...

Dosage: SOLUTION;ORAL

More Information on Dosage

SOTYLIZE family patents

Family Patents

17. Thyquidity patents expiration

THYQUIDITY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050307 AZURITY Method for the preparation of a levothyroxine solution
Aug, 2031

(7 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 30 November, 2020

Treatment: NA

Dosage: SOLUTION;ORAL

How can I launch a generic of THYQUIDITY before it's drug patent expiration?
More Information on Dosage

THYQUIDITY family patents

Family Patents

18. Triptodur Kit patents expiration

TRIPTODUR KIT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166181 AZURITY Slow release pharmaceutical composition made of microgranules
Jun, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-149) Jun 29, 2024
Orphan Drug Exclusivity(ODE) Jun 29, 2024
New Product(NP) Jun 29, 2020

Drugs and Companies using TRIPTORELIN PAMOATE ingredient

Market Authorisation Date: 29 June, 2017

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

TRIPTODUR KIT family patents

Family Patents

19. Xatmep patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855215 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US11116724 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US9259427 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US10231927 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

US10610485 AZURITY Methotrexate composition
Jan, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-137) Apr 25, 2024
Orphan Drug Exclusivity(ODE-138) Apr 25, 2024
Orphan Drug Exclusivity(ODE) Apr 25, 2024

Drugs and Companies using METHOTREXATE SODIUM ingredient

Market Authorisation Date: 25 April, 2017

Treatment: A method for treating acute lymphoblastic leukemia; Treatment of juvenile rheumatoid arthritis

Dosage: SOLUTION;ORAL

More Information on Dosage

XATMEP family patents

Family Patents

20. Zonisade patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529333 AZURITY Oral pharmaceutical composition comprising zonisamide and process of preparation thereof
Aug, 2038

(14 years from now)

US11478456 AZURITY Oral pharmaceutical composition comprising Zonisamide and process of preparation thereof
Aug, 2038

(14 years from now)

Drugs and Companies using ZONISAMIDE ingredient

Market Authorisation Date: 15 July, 2022

Treatment: A method of treating seizures

Dosage: SUSPENSION;ORAL

More Information on Dosage

ZONISADE family patents

Family Patents